The FDA granted Priority Review and orphan drug designations for Netspot. No serious adverse reactions have been identified. Netspot contributes to overall long-term cumulative radiation exposure, and patients should drink and urinate as often as possible during the first hours following administration to help reduce this risk. The results of all three studies confirmed the usefulness of Ga 68 dotatate images in finding the location of the neuroendocrine tumors. The first compared Ga 68 dotatate images of NETs to images obtained with an approved drug, and then confirmed with computed tomography (CT) and/ or magnetic resonance imaging (MRI) the second evaluated Ga 68 dotatate images using histopathology (the study of tissue changes caused by disease), or clinical follow up as reference standards and the third evaluated patients with NET recurrence using Ga 68 dotatate images. Three studies established the safety and effectiveness of Netspot. The uptake of Ga 68 dotatate may need to be confirmed by histopathology or other assessments. This uptake can also be seen in a variety of other tumor types or other pathologic conditions, or might occur as a normal variant. The uptake of Ga 68 dotatate reflects the level of somatostatin receptor density in NETs. Netspot is supplied as a sterile, single-dose kit for preparation of Ga 68 dotatate injection for intravenous use. This information is important for planning the appropriate course of therapy.” “Netspot provides another diagnostic tool whose results will help clinicians determine the location and extent of the tumor. “Use of advanced imaging techniques to detect rare neuroendocrine tumors at an early stage in patients is critical,” said Libero Marzella, M.D., Ph.D., director of the Division of Medical Imaging Products in the FDA’s Center for Drug Evaluation and Research. Ga 68 dotatate, a positron emitting analogue of somatostatin, works by binding to such receptors.
NETs have receptors for somatostatin, a hormone that regulates the endocrine system. These cells are found throughout the body in organs, such as the stomach, intestines, pancreas, lungs and other locations. NETs are rare noncancerous (benign) or cancerous (malignant) tumors that develop in the hormone-producing cells of the body’s neuroendocrine system. This radioactive probe will help locate tumors in adult and pediatric patients with the rare condition, somatostatin receptor positive neuroendocrine tumors (NETs). Food and Drug Administration today approved Netspot, the first kit for the preparation of gallium Ga 68 dotatate injection, a radioactive diagnostic agent for positron emission tomography (PET) imaging. Here’s the FDA Press release from the FDA website!įDA approves new diagnostic imaging agent to detect rare neuroendocrine tumors We’ve all been waiting for this very news!!
0 kommentar(er)
